Novo Nordisk gains following the success of early-phase clinical trials for its obesity drug 📢

Shares of Novo Nordisk (NOVOB.DK) rose by more than 10% following the publication of early-phase clinical trial results for a new obesity treatment. The study focused on a substance called amycretin, a unimolecular GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous administration.

According to the results, patients experienced a 9.7% reduction in body weight after 20 weeks, 16.2% after 28 weeks, and 22.08% after 36 weeks. In contrast, those treated with placebo saw an estimated weight gain of 1.9%, 2.3%, and 2.0%, respectively.

Based on these findings, Novo Nordisk plans to further develop amycretin clinically for adults with overweight or obesity.

The company's stock surged by over 10% following news of the successful clinical trial results. Novo Nordisk has been in a downward trend since mid-2024, at one point falling below 550 DKK, a level last seen before the publication of the first significant studies on the potential impact of the drug Wegovy on reducing the risk of heart disease in patients, which the company presented in August 2023. Source: xStation.

31 October 2025, 7:08 PM

Daily summary: Sentiments on Wall Street stall at the end of the week🗽US Dollar gains

31 October 2025, 4:08 PM

AbbVie near 1-month low after earnings report 📉

31 October 2025, 3:14 PM

Wall Street optimism tempers amid falling odds of December Fed rate cut

31 October 2025, 11:25 AM

DE40: Decline of sentiment in Europe

stocks

Cookie name	Description
SERVERID
userBranchSymbol	Expiration date 1 day
test_cookie	Expiration date 1 hour
adobe_unique_id	Expiration date 364 days
__hssc	Expiration date 1 hour
SESSID	Expiration date 1 day
__cf_bm	Expiration date 1 hour
intercom-id-iojaybix	Expiration date 270 days
intercom-session-iojaybix	Expiration date 6 days
xtbCookiesSettings	Expiration date 364 days
TS5b68a4e1027
countryIsoCode
xtbLanguageSettings	Expiration date 364 days
userPreviousBranchSymbol	Expiration date 364 days
intercom-device-id-iojaybix	Expiration date 270 days
__cfruid
_cfuvid

Cookie name	Description
_gid	Expiration date 1 day
_gat_UA-98728395-1	Expiration date 1 hour
_gat_UA-121192761-1	Expiration date 1 hour
_gcl_au	Expiration date 89 days
_ga_CBPL72L2EC	Expiration date 729 days
_ga	Expiration date 729 days
__hstc	Expiration date 179 days
__hssrc
_vwo_uuid_v2	Expiration date 365 days
_ga_TC79BEJ20L	Expiration date 729 days
_vwo_uuid	Expiration date 365 days
_vwo_ds	Expiration date 29 days
_vwo_sn	Expiration date 1 hour
_vis_opt_s	Expiration date 99 days
_vis_opt_test_cookie
af_id	Expiration date 394 days
afUserId	Expiration date 730 days
AF_SYNC	Expiration date 6 days
AnalyticsSyncHistory	Expiration date 29 days

Cookie name	Description
MUID	Expiration date 389 days
_omappvp	Expiration date 3998 days
_omappvs	Expiration date 1 hour
_uetsid	Expiration date 1 day
_uetvid	Expiration date 389 days
_fbp	Expiration date 89 days
fr	Expiration date 89 days
_ttp	Expiration date 89 days
_tt_enable_cookie	Expiration date 89 days
hubspotutk	Expiration date 179 days
IDE	Expiration date 389 days
YSC
VISITOR_INFO1_LIVE	Expiration date 179 days
li_sugr	Expiration date 89 days
guest_id_marketing	Expiration date 729 days
guest_id_ads	Expiration date 729 days
guest_id	Expiration date 729 days
muc_ads	Expiration date 729 days
VISITOR_PRIVACY_METADATA	Expiration date 179 days
MSPTC	Expiration date 389 days

Cookie name	Description
bcookie	Expiration date 364 days
lidc	Expiration date 1 day
UserMatchHistory	Expiration date 29 days
bscookie	Expiration date 364 days
li_gc	Expiration date 179 days
personalization_id	Expiration date 729 days

Novo Nordisk gains following the success of early-phase clinical trials for its obesity drug 📢

Join over 2 000 000 XTB Group Clients from around the world